Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 269605, 9 pages
http://dx.doi.org/10.1155/2014/269605
Review Article

Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?

1Imanova Ltd., Centre for Imaging Sciences, Imperial College Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
2GlaxoSmithKline Global Imaging Unit, Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex UB11 1BT, UK
3Early Phase Oncology Clinical Investigation, Eli Lilly Corporate Center, Building 31/4, 893 S. Delaware Street, Indianapolis, IN 46285, USA

Received 6 June 2014; Accepted 18 July 2014; Published 18 August 2014

Academic Editor: Masahiro Ono

Copyright © 2014 Azeem Saleem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Bergström, A. Grahnén, and B. Långström, “Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development,” European Journal of Clinical Pharmacology, vol. 59, no. 5-6, pp. 357–366, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Kapur, R. Zipursky, C. Jones, G. Remington, and S. Houle, “Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia,” The American Journal of Psychiatry, vol. 157, no. 4, pp. 514–520, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. Matthews, E. A. Rabiner, J. Passchier, and R. N. Gunn, “Positron emission tomography molecular imaging for drug development,” British Journal of Clinical Pharmacology, vol. 73, no. 2, pp. 175–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Natarajan, Y. Xie, M. R. Baer, and D. D. Ross, “Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance,” Biochemical Pharmacology, vol. 83, no. 8, pp. 1084–1103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. K. Vadlapatla, A. D. Vadlapudi, D. Pal, and A. K. Mitra, “Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes,” Current Pharmaceutical Design, vol. 19, no. 40, pp. 7126–7140, 2013. View at Google Scholar
  6. A. Saleem and P. M. Price, “Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure,” Clinical Cancer Research, vol. 14, no. 24, pp. 8184–8190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. A. M. S. Van Dongen and M. J. W. D. Vosjan, “Immuno-positron emission tomography: shedding light on clinical antibody therapy,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 4, pp. 375–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie et al., “How to improve R&D productivity: the pharmaceutical industry's grand challenge,” Nature Reviews Drug Discovery, vol. 9, no. 3, pp. 203–214, 2010. View at Publisher · View at Google Scholar
  9. B. Pagliara, “A record year for approvals,” MedNous, vol. 7, no. 2, pp. 6–8, 2012. View at Google Scholar
  10. E. O. Aboagye, A. Saleem, V. J. Cunningham, S. Osman, and P. M. Price, “Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer,” Cancer Research, vol. 61, no. 13, pp. 4937–4941, 2001. View at Google Scholar · View at Scopus
  11. A. Saleem, J. Yap, S. Osman et al., “Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action,” The Lancet, vol. 355, no. 9221, pp. 2125–2131, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Saleem, G. D. Brown, F. Brady et al., “Metabolic activation of temozolomide measured in vivo using positron emission tomography,” Cancer Research, vol. 63, no. 10, pp. 2409–2415, 2003. View at Google Scholar · View at Scopus
  13. L. Rosso, C. S. Brock, J. M. Gallo et al., “A new model for prediction of drug distribution in tumor and normal tissues: Pharmacokinetics of temozolomide in glioma patients,” Cancer Research, vol. 69, no. 1, pp. 120–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Saleem, R. J. Harte, J. C. Matthews et al., “Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1421–1429, 2001. View at Google Scholar · View at Scopus
  15. D. J. Propper, J. De Bono, A. Saleem et al., “Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 203–210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Saleem, J. C. Matthews, M. Ranson et al., “Molecular imaging and pharmacokinetic analysis of carbon-11 labeled antisense oligonucleotide LY2181308 in cancer patients,” Theranostics, vol. 1, pp. 290–301, 2011. View at Google Scholar
  17. D. C. Talbot, M. Ranson, J. Davies et al., “Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study,” Clinical Cancer Research, vol. 16, no. 24, pp. 6150–6158, 2010. View at Publisher · View at Google Scholar
  18. A. A. M. van der Veldt, N. H. Hendrikse, E. F. Smit et al., “Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 10, pp. 1950–1958, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K. A. Kurdziel, J. D. Kalen, J. I. Hirsch et al., “Human dosimetry and preliminary tumor distribution of 18F- fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT,” Journal of Nuclear Medicine, vol. 52, no. 9, pp. 1339–1345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Saleem, “Brain and tumor penetration of carbon-11–labeled lapatinib ([11C]Lap) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC): ASCO Annual Meeting 2013, Chicago, USA,” Journal of Clinical Oncology, vol. 31, supplement, abstract 635, 2013. View at Google Scholar
  21. I. Bahce, E. F. Smit, M. Lubberink et al., “Development of [11C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status,” Clinical Cancer Research, vol. 19, no. 1, pp. 183–193, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Stewart and J. J. Erasmus, “Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor,” Journal of Thoracic Oncology, vol. 6, no. 7, pp. 1149–1151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. A. Memon, B. Weber, M. Winterdahl et al., “PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer,” British Journal of Cancer, vol. 105, no. 12, pp. 1850–1855, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. P. K. E. Börjesson, Y. W. S. Jauw, R. De Bree et al., “Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients,” Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1828–1836, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. E. C. Dijkers, T. H. O. Munnink, J. G. Kosterink et al., “Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer,” Clinical Pharmacology and Therapeutics, vol. 87, no. 5, pp. 586–592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. E. Mortimer, J. R. Bading, D. M. Colcher et al., “Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET,” Journal of Nuclear Medicine, vol. 55, no. 1, pp. 23–29, 2014. View at Google Scholar
  27. J. C. Bendell, S. M. Domchek, H. J. Burstein et al., “Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma,” Cancer, vol. 97, no. 12, pp. 2972–2977, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. N. J. Abbott, A. A. Patabendige, D. E. Dolman, S. R. Yusof, and D. J. Begley, “Structure and function of the blood-brain barrier,” Neurobiology of Disease, vol. 37, no. 1, pp. 13–25, 2010. View at Google Scholar
  29. R. Nau, F. Sörgel, and H. Eiffert, “Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections,” Clinical Microbiology Reviews, vol. 23, no. 4, pp. 858–883, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Slobbe, A. J. Poot, A. D. Windhorst, and G. A. M. S. Van Dongen, “PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET,” Drug Discovery Today, vol. 17, no. 21-22, pp. 1175–1187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. Ö. Lindhe, A. Thibblin, G. Antoni et al., “PET imaging of c-Met expression in non-human primates using [18F]AH113804,” in Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, Chicago, Ill, USA, 2012.
  32. C. Dittrich, V. Dieras, P. Kerbrat et al., “Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer,” Investigational New Drugs, vol. 21, no. 3, pp. 347–352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Dittrich, B. Coudert, L. Paz-Ares et al., “Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer,” European Journal of Cancer, vol. 39, no. 3, pp. 330–334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Caponigro, C. Dittrich, J. B. Sorensen et al., “Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer,” European Journal of Cancer, vol. 38, no. 1, pp. 70–74, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. C. S. Dence, R. Laforest, X. Sun, T. L. Sharp, M. J. Welch, and R. H. MacH, “Radiochemical synthesis, rodent biodistribution and tumor uptake, and dosimetry calculations of [11C] methylated LY2181308,” Molecular Imaging and Biology, vol. 12, no. 6, pp. 608–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. European Medicines Agency, Guideline on the Requirements to the Chemical and Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products in Clinical Trials, European Commission, London, UK, 2006, Edited by Committee for Medicinal Products for Human Use (CHMP).
  37. W. G. Herrington, D. C. Talbot, M. M. Lahn et al., “Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma,” American Journal of Kidney Diseases, vol. 57, no. 2, pp. 300–303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. H. P. Erba, H. Sayar, M. Juckett et al., “Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML),” Investigational New Drugs, vol. 31, no. 4, pp. 1023–1034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Wiechno et al., “Randomized phase II study with window-design to evaluate anti-tumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC),” in Proceedings of the American Soceity of Clinical Oncology Annual Meeting, Journal of Clinical Oncology, Chicago, Ill, USA, 2013.
  40. D. Talbot, F. H. Blackhall, D. Kowalski et al., “A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS),” in Proceedings of the American Soceity of Clinical Oncology, Chicago, Ill, USA, 2013.
  41. E. A. I. Directorate-General, EU Guidelines to Good Medical Practice Medicianl Products for Human amd Veterinary Use, Edited by: C. G. Pharmaceuticals, European Commission, Brussels, Belgium, 2008.
  42. A. Verbruggen, H. H. Coenen, J. Deverre et al., “Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 11, pp. 2144–2151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Zanotti-Fregonara and R. B. Innis, “Suggested pathway to assess radiation safety of11C-labeled PET tracers for first-in-human studies,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 3, pp. 544–547, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Zanotti-Fregonara, A. A. Lammertsma, and R. B. Innis, “Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 11, pp. 1781–1783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. A. J. Poot, P. Slobbe, N. H. Hendrikse, A. D. Windhorst, and G. van Dongen, “Imaging of TKI-target interactions for personalized cancer therapy,” Clinical Pharmacology and Therapeutics, vol. 93, no. 3, pp. 239–241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Jones, P. Price, and B. Tavitian, “Realizing the full potential of PET for measuring the biodistribution of novel anticancer agents,” Journal of Nuclear Medicine, vol. 52, no. 9, p. 1500, 2011. View at Publisher · View at Google Scholar · View at Scopus